EGFR and non-small cell lung carcinoma: These EGFR-TKIs (targeted therapies for patients with EGFR-mutant NSCLC) have been established as standard first-line treatments according to pivotal phase III trials that reported an improved objective response rate of approximately 70% and significantly longer progression-free survival (PFS) (range, 8.0–13.7 months) with EGFR-TKIs than with conventional chemotherapy6–8.